Condition: Slow-Flow Vascular Malformation · Fast-Flow Vascular Malformation · Vascular Malformations · Sponsor: Murdoch Childrens Research Institute
Recent studies have demonstrated that growth of vascular malformations can be driven by genetic variants in one of 2 signalling pathways. Targeted drugs specific to these pathways have been developed and shown to be effective in treating cancer. This study will describe the effectiveness of (i) 48 weeks of alpelisib therapy for participants with slow-flow vascular malformations and a gene mutation in one of these signalling pathways (module 1) and (ii) 48 weeks of mirdametinib therapy for participants with fast-flow vascular malformations and a gene mutations in the other signalling pathway (module 2).
This description comes directly from the study's public registry record.
Michelle de Silva, PhD · +61399366109 · michelle.desilva@vcgs.org.au
Tony Penington, MBBS, FRACS · +61383416200 · tony.penington@rch.org.au
Always discuss trial participation with your own doctor first.
| Peter MacCallum Cancer Centre | Parkville, Victoria, Australia | Recruiting |
| The Royal Children's Hospital | Parkville, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05983159